Court Opinion

ID: 4909261
Source: CourtListenerOpinion
Date Created: 2021-09-08 20:02:34.336367+00
Date Added: 2024-06-11T08:13:19.707874
License: Public Domain

FILED
                            NOT FOR PUBLICATION
                                                                               SEP 8 2021
                    UNITED STATES COURT OF APPEALS                         MOLLY C. DWYER, CLERK
                                                                            U.S. COURT OF APPEALS

                            FOR THE NINTH CIRCUIT

B.P., on behalf of themselves and all            No.   20-15974
others similarly situated; et al.,
                                                 D.C. Nos.    2:16-cv-02138-HRH
              Plaintiffs-Appellees,                           2:16-cv-2373-HRH
                                                              2:16-cv-2660-HRH
 v.                                                           2:16-cv-2775-HRH
                                                              2:16-cv-3599-HRH
RAMESH BALWANI,

              Defendant-Appellant,               MEMORANDUM*

 and

WALGREENS BOOTS ALLIANCE,
INC.; WALGREENS ARIZONA DRUG
COMPANY,

              Defendants.

B.P., on behalf of themselves and all            No.   20-15976
others similarly situated; et al.,
                                                 D.C. Nos.    2:16-cv-02138-HRH
              Plaintiffs-Appellees,                           2:16-cv-2373-HRH
                                                              2:16-cv-2660-HRH
 v.                                                           2:16-cv-2775-HRH
                                                              2:16-cv-3599-HRH
WALGREENS BOOTS ALLIANCE,
INC.; WALGREENS ARIZONA DRUG

       *
             This disposition is not appropriate for publication and is not precedent
except as provided by Ninth Circuit Rule 36-3.
COMPANY,

              Defendants-Appellants,

 and

RAMESH BALWANI,

              Defendant.

                    Appeal from the United States District Court
                             for the District of Arizona
                 H. Russel Holland, Senior District Judge, Presiding

                        Argued and Submitted August 9, 2021
                             San Francisco, California

Before: SILER,** CHRISTEN, and FORREST, Circuit Judges.

       Defendants appeal the district court’s order granting class certification as to

plaintiffs’ claims pursuant to the Arizona Consumer Fraud Act (CFA), California’s

Unfair Competition Law, California’s False Advertising Law, racketeering in

violation of 18 U.S.C. § 1962(c), battery, and medical battery. We review a district

court’s class-certification order for abuse of discretion. Pulaski & Middleman,

LLC v. Google, Inc., 802 F.3d 979, 984 (9th Cir. 2015). We have jurisdiction

pursuant to 28 U.S.C. § 1292(e) and Federal Rule of Civil Procedure 23(f), and we

       **
            The Honorable Eugene E. Siler, United States Circuit Judge for the
U.S. Court of Appeals for the Sixth Circuit, sitting by designation.
                                           2
affirm in part, reverse in part, and remand. Because the parties are familiar with

the facts, we do not recite them here.

       1.     Walgreens argues the district court erred by finding that the named

plaintiffs adequately represented absent class members’ claims because the named

plaintiffs dropped their emotional distress, retesting, and subsequent medical

treatment claims. See Fed. R. Civ. P. 23(a)(4). Walgreens argues the named

plaintiffs created a conflict of interest with absent class members by giving away

valuable theories of recovery that absent class members will be precluded from

raising in the future.

       Conflicts of interest defeat legal adequacy where the interests of one

subclass “tug[] against” the interests of another. See Amchem Prods., Inc. v.

Windsor, 521 U.S. 591, 626 (1997). The district court reasoned that plaintiffs

voluntarily dismissed the emotional distress and subsequent medical treatment

claims for all class members, including themselves, because they concluded these

claims are not suitable for classwide resolution. The district court concluded that,

because of the disparity between litigation costs and the amount of recoverable

damage for any individual litigant, absent plaintiffs would likely be unable to

recover at all without class certification. The district court did not err by

concluding that plaintiffs dropped their emotional distress and subsequent medical

                                            3
treatment claims for the strategic benefit of the entire class, and there is no conflict

of interest. Walgreens also argues that the district court “improperly passed the

resolution of this conflict on to the absent class members by relying solely on their

opt-out right” and failed to consider the value of absent class members’ dropped

claims. However, the district court did not make its adequacy determination solely

based on absent class members’ opt-out rights; it merely observed that absent class

members who wish to pursue them may opt out, and considered this as a factor in a

broader analysis. Therefore, we affirm the district court’s adequacy determination.

      2.     Defendant Balwani submits that the district court improperly

disregarded his defense when it made its predominance determination. Balwani

seeks to argue that certain plaintiffs received accurate test results and experienced

improved health outcomes, and they therefore did not suffer injury (i.e. they got

what they paid for).

      This court has sometimes concluded that a class does not meet the

predominance requirement in cases where liability could be established only with

individualized evidence. See, e.g., Mazza v. Am. Honda Motor Co., 666 F.3d 581,

596 (9th Cir. 2012); Berger v. Home Depot USA, Inc., 741 F.3d 1061, 1069 (9th

Cir. 2014), abrogated on other grounds by Microsoft Corp. v. Baker, 137 S. Ct.

1702, 1712 (2017). Here, the district court determined that a single common issue

                                            4
is central to plaintiffs’ case: whether Theranos and Walgreens’ blood testing

services were capable of producing reliable results. The district court concluded

that this issue predominates over individual questions of test result accuracy.

Balwani’s defense does not address this central issue of liability because whether

individual tests were in fact accurate is not relevant to representations that were

made concerning the reliability of the testing. Because “more important questions

apt to drive the resolution of the litigation are given more weight in the

predominance analysis over individualized questions which are of considerably

less significance,” Ruiz Torres v. Mercer Canyons Inc., 835 F.3d 1125, 1134 (9th

Cir. 2016), we conclude that the district court did not abuse its discretion by

finding predominance.

      3.     Walgreens argues the district court erred by certifying the battery and

medical battery claims because Walgreens employees did not touch all plaintiffs,

and determining who conducted any given plaintiff’s test is an individualized

inquiry that defeats predominance. Plaintiffs submit that Walgreens and Theranos

subjected them to offensive touching without consent on a classwide basis, and that

this claim can be established through common proof.

      “An actor is subject to liability to another for battery if the actor

intentionally engages in an act that results in harmful or offensive contact with the

                                           5
person of another.” Duncan v. Scottsdale Med. Imaging, Ltd., 70 P.3d 435, 439

(Ariz. 2003) (en banc) (citing Restatement (Second) of Torts §§ 13, 18 (1965)). To

make a classwide battery or medical battery claim, plaintiffs must be able to show

that Walgreens is liable for all blood draws, including those conducted by

Theranos employees. See id. Plaintiffs’ contention that they need only prove that

Walgreens intentionally engaged in some act that resulted in blood draws—not

necessarily the touching itself—is unsupported by Arizona law. The district court

dismissed plaintiffs’ agency and joint venture theories because Walgreens and

Theranos were not in an agency relationship. While plaintiffs argue they can show

that Walgreens may be liable for medical battery based on an aiding and abetting

theory, plaintiffs cannot make a derivative aiding and abetting battery claim

without a certifiable battery claim. See Patel v. Verde Valley Med. Ctr., Nos. CV-

05-1129/2926-PCT-MHM, 2009 WL 3270883, at *4 (D. Ariz. Oct. 8, 2009).

Plaintiffs maintain that they possess a spreadsheet containing common evidence

regarding who drew each subclass member’s blood. We reverse class certification

as to the battery and medical battery claims and remand to the district court to limit

this class to plaintiffs who had blood drawn by Walgreens employees, such that no

claims impute liability for battery or medical battery on one defendant for a

touching conducted by another defendant’s employee.

                                           6
      4.     Balwani argues the district court abused its discretion because the

Arizona Consent Decree defeated the Fed. R. Civ. P. 23(b)(3) superiority

requirement. We conclude, however, that the district court did not abuse its

discretion while conducting a superiority analysis pursuant to Zinser v. Accufix

Research Institute, Inc., 253 F.3d 1180, 1189 (9th Cir. 2001). In assessing the

second Zinser factor, the district court reasoned that the Arizona Consent Decree

“did not comprehend the full scope of damages that might be available,” and that it

did not include a battery or medical battery claim. Plaintiffs’ California statutory

claims are also unaffected by the Arizona Consent Decree. Contrary to defendants’

argument, Kamm v. California City Development Company does not hold that a

prior public settlement necessarily defeats superiority for future class actions. 509

F.2d 205, 211 (9th Cir. 1975). On the facts of this case, the district court did not

abuse its discretion. Separately, Balwani forfeited the argument that his criminal

prosecution is a superior method to adjudicate the class claims.

      5.     Finally, Walgreens argues the district court erred in certifying

plaintiffs’ RICO and Arizona CFA claims for punitive damages under Fed. R. Civ.

P. 23(b)(3) because the Arizona plaintiffs have already been compensated for their

actual damages by the Arizona Consent Decree, and they are therefore ineligible

                                           7
for compensatory damages, and thus punitive damages, in this action.

      Under Arizona law, a plaintiff must be entitled to actual damages before

being eligible for punitive damages. Wyatt v. Wehmueller, 806 P.2d 870, 874

(Ariz. 1991) (en banc). Plaintiffs in this case may have suffered a compensable

injury that entitled them to damages according to the Arizona Consent Decree,

even though those compensatory damages have already been paid. We thus

conclude the Consent Decree does not bar plaintiffs’ RICO treble damages

recovery so long as plaintiffs establish defendants’ liability for actual damages and

additional damages are “offset” by the amount already paid. See Uthe Tech. Corp.

v. Aetrium, Inc., 808 F.3d 755, 760 (9th Cir. 2015). Similarly, plaintiffs may also

recover under the Arizona CFA because the “offset rule” prevents any double

recovery of those statutory damages. See City of San Jose v. Price Waterhouse,

No. 91-16489, 1993 WL 83495 (9th Cir. March 23, 1993). The district court did

not abuse its discretion.

      AFFIRMED in part, REVERSED in part, and REMANDED. Each

party to bear its own costs.

                                          8